Volasertib
Volasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 3 | — | — | — | — | 3 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 2 | — | — | — | — | 2 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
| Megakaryoblastic leukemia acute | D007947 | C94.2 | 1 | — | — | — | — | 1 | |
| Monocytic leukemia acute | D007948 | 1 | — | — | — | — | 1 | ||
| Myelomonocytic leukemia acute | D015479 | C92.5 | 1 | — | — | — | — | 1 | |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | C85.9 | 1 | — | — | — | — | 1 | |
| T-cell lymphoma | D016399 | 1 | — | — | — | — | 1 | ||
| Leukemia | D007938 | C95 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VOLASERTIB |
| INN | volasertib |
| Description | Volasertib (also known as BI 6727) is an experimental small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.
|
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 755038-65-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1233528 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12062 |
| UNII ID | 6EM57086EA (ChemIDplus, GSRS) |
Target
Agency Approved
PLK1
PLK1
Organism
Homo sapiens
Gene name
PLK1
Gene synonyms
PLK
NCBI Gene ID
Protein name
serine/threonine-protein kinase PLK1
Protein synonyms
cell cycle regulated protein kinase, PLK-1, polo (Drosophia)-like kinase, Polo-like kinase 1, Serine/threonine-protein kinase 13, STPK13
Uniprot ID
Mouse ortholog
Plk1 (18817)
serine/threonine-protein kinase PLK1 (Q07832)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 765 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more